Biogen reported positive topline results from the company’s Phase II CONVEY trial of vixotrigine for the treatment of small fiber neuropathy (SFN).
Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
